Literature DB >> 20854805

Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species.

Wei Guo1, Xiaoli Wei, Shuhong Wu, Li Wang, Henry Peng, Ji Wang, Bingliang Fang.   

Abstract

NSC-741909 (1-[(4-chlorophenyl)methyl]-1H-Indole-3-methanol) is a novel anticancer agent that is highly active against several NCI-60 cancer cell lines. This agent induces sustained activation of mitogen-activated protein kinases (MAPK), including JNK and p38 MAP kinases. However, the mechanisms of its selective antitumor activity in some cancer cell lines remain unknown. We tested the combined effects of NSC-741909 and several kinase inhibitors that target the Raf/MEK/ERK1/2 or PI3K/AKT pathways in two sensitive lung cancer cells. We found that PD98059 (2'-amino-3'-methoxyflavone), a flavone derivative and a selective MEK inhibitor, can dramatically block the cell killing effect of NSC-741909. To determine whether this inhibitory effect is associated with MEK inhibition or other mechanisms, we evaluated the effects of other MEK inhibitors with different chemical structures and flavone derivatives that do not have an effect on MEK. We found that several flavonoids can markedly block NSC-741909-induced apoptosis and JNK activation in a time-dependent manner, regardless of whether they inhibit MEK or not. In contrast, NSC-741909-induced JNK activation and apoptosis were not blocked by other MEK-specific inhibitors U0126 and CI1040. Our results also showed that NSC-741909 induced a dramatic increase of reactive oxygen species in sensitive cells and that flavonoids effectively blocked the NSC-741909-induced reactive oxygen species production which are associated with flavonoids' antagonistic effects on NSC-741909-induced JNK activation and apoptosis. Those results demonstrated that flavonoids-mediated antagonist effect is through scavenging of reactive oxygen species. Our results may have implication on the design of clinical evaluation of antitumor activity of NSC-741909 or its analogues.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854805      PMCID: PMC2967662          DOI: 10.1016/j.ejphar.2010.08.057

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  42 in total

1.  Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).

Authors:  J Nemunaitis; J Cox; W Meyer; A Courtney; G Mues
Journal:  Am J Clin Oncol       Date:  1997-10       Impact factor: 2.339

2.  Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling.

Authors:  Kuntebommanahalli N Thimmaiah; John B Easton; Glen S Germain; Christopher L Morton; Shantaram Kamath; John K Buolamwini; Peter J Houghton
Journal:  J Biol Chem       Date:  2005-07-11       Impact factor: 5.157

3.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.

Authors:  S J Leevers; H F Paterson; C J Marshall
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

Review 4.  The JNK signal transduction pathway.

Authors:  Claire R Weston; Roger J Davis
Journal:  Curr Opin Genet Dev       Date:  2002-02       Impact factor: 5.578

5.  The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.

Authors:  David J Panka; Wei Wang; Michael B Atkins; James W Mier
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

6.  PD98059 attenuates hydrogen peroxide-induced cell death through inhibition of Jun N-Terminal Kinase in HT29 cells.

Authors:  B S Salh; J Martens; R S Hundal; N Yoganathan; D Charest; A Mui; A Gómez-Muñoz
Journal:  Mol Cell Biol Res Commun       Date:  2000-09

7.  Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.

Authors:  Yun Dai; Mohamed Rahmani; Steven Grant
Journal:  Oncogene       Date:  2003-10-16       Impact factor: 9.867

8.  SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes.

Authors:  A M Badger; M N Cook; M W Lark; T M Newman-Tarr; B A Swift; A H Nelson; F C Barone; S Kumar
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

9.  A JNK-dependent pathway is required for TNFalpha-induced apoptosis.

Authors:  Yibin Deng; Xiaoyang Ren; Lin Yang; Yahong Lin; Xiangwei Wu
Journal:  Cell       Date:  2003-10-03       Impact factor: 41.582

10.  Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies.

Authors:  Bea Pauwels; Annelies E C Korst; Christel M J de Pooter; Greet G O Pattyn; Hilde A J Lambrechts; Marc F D Baay; Filip Lardon; Jan B Vermorken
Journal:  Cancer Chemother Pharmacol       Date:  2003-01-22       Impact factor: 3.333

View more
  8 in total

1.  Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.

Authors:  Xiaoying Liu; Wei Guo; Shuhong Wu; Li Wang; Ji Wang; Bingbing Dai; Edward S Kim; John V Heymach; Michael Wang; Luc Girard; John Minna; Jack A Roth; Stephen G Swisher; Bingliang Fang
Journal:  Biochem Pharmacol       Date:  2012-02-22       Impact factor: 5.858

2.  Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380.

Authors:  Shuhong Wu; Li Wang; Xiao Huang; Mengru Cao; Jing Hu; Hongyu Li; Hui Zhang; Xiaoping Sun; Qing H Meng; Wayne L Hofstetter; Jack A Roth; Stephen G Swisher; Bingliang Fang
Journal:  Bioorg Med Chem       Date:  2014-08-14       Impact factor: 3.641

Review 3.  RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

Authors:  Bingliang Fang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-09-07       Impact factor: 3.848

Review 4.  Predictive biomarkers in precision medicine and drug development against lung cancer.

Authors:  Bingliang Fang; Reza J Mehran; John V Heymach; Stephen G Swisher
Journal:  Chin J Cancer       Date:  2015-07-02

5.  Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.

Authors:  Xiao Huang; Mengru Cao; Shuhong Wu; Li Wang; Jing Hu; Reza J Mehran; Jack A Roth; Stephen G Swisher; Rui-Yu Wang; Hagop M Kantarjian; Michael Andreeff; Xiaoping Sun; Bingliang Fang
Journal:  Oncotarget       Date:  2017-11-01

6.  Genetic Interactions of STAT3 and Anticancer Drug Development.

Authors:  Bingliang Fang
Journal:  Cancers (Basel)       Date:  2014-03-06       Impact factor: 6.639

Review 7.  Development of synthetic lethality anticancer therapeutics.

Authors:  Bingliang Fang
Journal:  J Med Chem       Date:  2014-06-13       Impact factor: 7.446

Review 8.  Defeat mutant KRAS with synthetic lethality.

Authors:  Xiufeng Pang; Mingyao Liu
Journal:  Small GTPases       Date:  2016-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.